10-KPeriod: FY2008

CARDINAL HEALTH INC Annual Report, Year Ended Jun 30, 2008

Filed August 27, 2008For Securities:CAH

Summary

Cardinal Health, Inc. (CAH) filed its 2008 10-K report, reflecting a significant period of strategic re-evaluation and operational adjustments. A key development is the active exploration of separating its Healthcare Supply Chain Services and Clinical and Medical Products segments, potentially through a tax-free spin-off of the latter. This move signals a desire to streamline operations and potentially unlock value by creating more focused entities. The company's business is broadly categorized into pharmaceutical and medical supply chain services, clinical technologies, and medical products, each facing distinct competitive landscapes and regulatory environments. Investors should note the company's substantial revenue concentration with its top customers, particularly CVS Caremark and Walgreen Co., which collectively represented a significant portion of fiscal 2008 revenue, highlighting potential risks associated with customer retention. The report also details extensive regulatory oversight across its various segments, including FDA, DEA, and other health agencies, alongside ongoing efforts to ensure compliance and manage associated risks. The company's acquisition and divestiture activities demonstrate a dynamic approach to portfolio management, aiming to align with strategic objectives.

Financial Highlights

31 data points
Beta

Revenue

$87.41B

4.3% Gross Margin

Net Income

$1.30B

1.5% Net Margin

Cash & Equivalents

$808.80M

Free Cash Flow

$1.54B

Financial Statements
Beta
Revenue$87.41B
Cost of Revenue$83.63B
Gross Profit$3.78B
SG&A Expenses$2.34B
Operating Income$1.39B
Interest Expense$136.10M
Net Income$1.30B
Shares Outstanding (Basic)358.20M
Shares Outstanding (Diluted)364.00M

Key Highlights

  • 1Cardinal Health is actively exploring a separation of its Healthcare Supply Chain Services and Clinical and Medical Products segments, possibly via a spin-off of the Clinical and Medical Products business.
  • 2The company's largest customers, CVS Caremark and Walgreen Co., accounted for 22% and 19% of revenue respectively in fiscal 2008, with the top five customers representing 52% of total revenue.
  • 3The company operates across four main segments (as of FY2008): Pharmaceutical Supply Chain Services, Medical Supply Chain Services, Clinical Technologies and Services, and Medical Products and Technologies.
  • 4Significant acquisitions in recent years include ALARIS Medical Systems, VIASYS Healthcare, and Enturia Inc., indicating strategic growth through acquisition.
  • 5The company faces extensive regulatory scrutiny across its operations, including FDA, DEA, and state-level regulations, with potential for civil and criminal penalties for non-compliance.
  • 6Cardinal Health has undergone significant divestitures, including parts of its specialty distribution business and its Pharmaceutical Technologies and Services segment.
  • 7The company's pharmaceutical supply chain business relies heavily on manufacturer relationships, distribution service agreements, and managing price appreciation and rebates.

Frequently Asked Questions

As of the fiscal year ended June 30, 2008, Cardinal Health reported four primary segments: Healthcare Supply Chain Services—Pharmaceutical; Healthcare Supply Chain Services—Medical; Clinical Technologies and Services; and Medical Products and Technologies. Effective July 1, 2008, the company began consolidating these into three reportable segments: Healthcare Supply Chain Services, Clinical and Medical Products, and All Other.

A significant risk lies in the concentration of revenue from a few large customers. In fiscal year 2008, CVS Caremark and Walgreen Co. alone accounted for approximately 41% of the company's revenue, with the top five customers representing 52%. The loss of one or more of these major customers could materially and adversely affect the company's financial results.

Cardinal Health announced in August 2008 that its Board of Directors is actively exploring a potential separation of its Healthcare Supply Chain Services and Clinical and Medical Products reportable segments. This separation could involve a tax-free spin-off of all or a portion of the Clinical and Medical Products segment into a separate, publicly traded company. A decision was expected within 60 to 90 days of the announcement.

The pharmaceutical supply chain business's gross margin is influenced by several factors, including customer discounts, manufacturer cash discounts, distribution service agreement fees, pharmaceutical price appreciation, and manufacturer rebates and incentives. The company engages in fee-for-service arrangements with manufacturers, typically for one to five-year terms, and works to manage inventory and pricing dynamics to maintain profitability in a low-margin business.